查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837113

经导管肺动脉瓣市场（按瓣膜类型、应用和最终用户划分）—2025-2032 年全球预测

Transcatheter Pulmonary Valve Market by Valve Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，经导管肺动脉瓣市场规模将成长至 1.5,169 亿美元，复合年增长率为 10.19%。

主要市场统计数据
基准年2024年 6976万美元
预计2025年 7676万美元
预测年份：2032年 1.5169亿美元
复合年增长率（%） 10.19%

经导管肺动脉瓣治疗的全面介绍，重点介绍临床进展、手术实践以及对相关人员的策略意义

经导管肺动脉瓣置换术已从一项实验性治疗转变为临床可行的治疗方案，解决了先天性和后天性右心室流出道功能障碍患者中尚未满足的重大医疗需求。经皮肺动脉瓣系统的经皮使临床医生能够提供一种比重复开胸手术创伤更小的治疗方案，从而降低手术全期併发症发生率，并缩短儿童和成人先天性心臟病患者的康復路径。手术技术的改进、影像学的进步以及对患者选择标准的更深入理解，改善了经导管肺动脉瓣置换术的疗效，并扩大了其临床适应症。

如今，临床实践强调心臟团队合作，整合先天性心臟疾病专家、介入科医生、心臟外科医生和高级影像专家。这种多学科方法优化了器材选择、介入策略和术后监测。随着手术操作经验的累积以及机构对患者追踪路径的规范化，该手术的安全性已得到改善，同时对有症状和无症状性病变的治疗阈值也得到了改善。监管部门的批准和真实世界註册数据进一步使经导管肺动脉瓣介入治疗合法化，促进了其在三级转诊中心和部分门诊手术中心的广泛应用。

从策略角度来看，设备製造商、医疗系统和临床研究人员应致力于将技术进步转化为可扩展的医疗模式。未来，需要在培训、上市后证据产生和供应链韧性方面进行协调一致的投资，以确保不同地区和不同医疗服务提供者都能平等地获得治疗并取得一致的治疗结果。

对改变肺瓣膜护理和提供者策略的技术、临床和操作变化的权威概述

在技​​术、临床和操作动态融合的推动下，肺动脉瓣治疗领域正在经历一场变革性转变。瓣膜设计的进步，包括改进的径向力分布、组织工程和输送系统的灵活性，正在扩大其解剖学适用性并减少入路挑战。增强的显像模式和融合引导平台能够在复杂的右心室流出道中实现精确的定位和尺寸测量，从而降低併发症率，并增强操作者对先前被认为是高风险的解剖区域的信心。

同时，随着瓣膜的长期耐久性和患者生活品质成为核心终点，临床模式正在转变。器械可回收性和模组化方法的创新，支持针对不同患者群体的分阶段手术和个人化治疗。监管生态系统正在适应混合证据模型，该模型将随机数据与高品质的註册研究相结合，从而加快了在未满足需求最大的领域获得有条件核准。付款人对基于价值的指标（例如降低再入院率、缩短住院时间以及改善长期功能）的兴趣日益浓厚。

在营运方面，卓越中心正在组建，以整合专业知识并简化患者诊疗路径，同时设备开发人员和影像处理公司联盟正在整合预测规划工具。因此，竞争格局正在从单一产品策略转向整合设备、影像通讯协定和临床培训的整合解决方案——重新定义高价值经导管肺部治疗的意义。

清楚分析 2025 年美国关税变化将如何重塑心臟设备领域的供应链、采购经济和战略製造决策。

美国将于2025年实施新关税，这为设备製造商和医疗保健提供者重新评估其供应链、采购和定价策略提供了一个独特的视角。对进口零件和组装设备征收的关税将影响采购的经济性，迫使製造商评估本地生产、近岸外包选项和其他采购方式，以保护净利率并维持与医院采购商的竞争性定价。对于依赖全球供应网路的组织而言，此类保护主义措施可能会增加前置作业时间和交易成本，从而加剧对多方采购和库存缓衝的需求。

临床项目和医院采购负责人将面临修改合约条款的谈判，这些条款将考虑进口相关附加税和设备供应的潜在变化。卫生系统必须在控製成本的必要性和优先考虑患者治疗结果的临床需求之间取得平衡。这通常需要临床负责人和采购团队之间进行透明的对话，就可接受的权衡取舍以及高风险患者的优先用药问题进行沟通。同时，製造商正在加快努力，实现零件供应商多元化，提升国内供应商的资质，并投资自动化製造，以抵销关税带来的成本压力。

政策反应和筹资策略最终将决定关税在多大程度上改变医疗器材的采用轨迹。积极主动地模拟关税敏感性和应急生产能力，并向付款人和医疗系统采购方清晰地传达临床价值的利益相关人员，将最有能力缓解2025年带来的营运中断。这种适应性态势将降低患者风险，并保持创新和更广泛临床应用的势头。

医疗设备、临床和最终用户细分揭示了产品特性和患者需求的交汇点，从而塑造了商业性和临床路径

精细的细分框架揭示了临床需求、产品差异化和最终用户行为在製定策略时相互交织的因素。根据瓣膜类型，市场主要分为两种：球囊扩张型和自扩张式瓣膜。球囊扩张型瓣膜包括 Melody 瓣膜和 Sapien 经导管瓣膜等成熟平台，这些平台已被证明效用于特定尺寸和导管结构的瓣膜。自扩张式瓣膜系统，以 Harmony 经导管肺动脉瓣膜和 Venus P 瓣膜等技术为代表，具有良好的顺应性和径向适应性，适用于范围更广且通常不规则的右心室流出道。这些瓣膜类型之间的技术权衡体现在各中心的临床选择标准、库存管理和训练要求。

基于应用的细分进一步细化了临床路径和证据需求。患者情况多种多样，包括复杂病症、肺动脉瓣逆流和肺动脉瓣狭窄，每种情况都有不同的动态考量和手术规划需求。针对混合病症的设备必须在密封、锚定和动态性能方面表现出多功能性，而主要针对狭窄或逆流的设备可以分别进行最佳化，以实现Low profile输送和增强径向支撑。门诊手术中心、心臟中心和医院各自拥有独特的基础设施、病例组合和采购模式。门诊手术中心优先考虑吞吐量和当日出院通讯协定，心臟中心强调复杂病例和多学科路径，而医院则在急性护理能力和广泛的住院能力之间取得平衡。

了解瓣膜类型、临床应用和最终用户环境如何相互作用，使製造商和供应商能够根据设备采用和结果监测的实际情况调整产品系列、培训计划和商业化计划。

简洁的区域概述，比较全球主要地区的采用趋势、法规环境和商业化路径

区域动态在塑造可及性、监管途径和商业化执行方面发挥核心作用。在美洲，成熟的卓越中心和介入性心臟病学生态系统，加上强大的临床网络和完善的报销框架，为先进经导管肺动脉介入治疗方案的早期应用创造了有利环境。该地区的市场准入和规模化发展得益于高手术量、集中的专业知识以及活跃的临床研究团队，这些团队能够产生上市后的安全性和性能数据。

欧洲、中东和非洲地区（EMEA）市场竞争激烈，监管环境、报销途径和基础设施差距各不相同，这些因素都会影响其采用率。西方市场通常在临床证据支持疗效改善的情况下能够快速采用，而更广泛的电子病历 (EMR) 市场和新兴非洲市场则优先考虑经济高效的解决方案和弹性供应链。这些地区的策略合作伙伴通常需要定价、能力建构专案和本地证据产生来推动采用。

亚太地区对先天性和结构性心臟疾病计画的投资正在加速，其战略重点是国内製造和创新中心。该地区的一些国家正在扩大心臟专科中心的规模，并推广区域临床登记，以指导适合特定族群解剖结构的器材。随着製造商不断探索监管途径和当地临床预期，跨境合作和技术转移也日益普遍。

对竞争定位、联盟策略和创新重点领域的深入概述，这些领域塑造了肺部瓣膜护理领域的公司级差异化

经导管肺动脉瓣的竞争格局由成熟的心血管器材製造商和敏捷的专业创新者所构成。领先的公司优先考虑一种平衡的方法，将器械工程与临床证据生成和医疗保健提供者教育相结合。器械製造商与先进成像公司之间的合作日益普遍，从而能够提供更可靠的术前规划和术中指导。与契约製造和材料科学公司建立策略联盟也增强了製造的扩充性和组件的品管。

创新管线强调耐用性、可交付性和对复杂解剖结构的适应性，越来越多的参与企业正在探索组织治疗和抗钙化技术，以延长瓣膜寿命。商业策略着重于提供配套服务，包括量角器、模拟训练和结果支持，以缩短新用户的学习曲线。与此同时，一些公司正在透过区域分销商和临床合作伙伴关係进行有针对性的地域扩张，而另一些公司则在监管和报销条件有利于高端定位的情况下，投资直接进入市场。

合併、收购和授权协议仍然是实现品类领先地位的策略性槓桿，尤其是在能够整合互补的影像、供应链和报销专业知识的情况下。将强大的临床项目与可扩展的生产和清晰的价值通讯相结合的组织，将最有可能获得持续的临床吸引力和机构采用。

为临床、製造和商业领导者提供可行的建议，以加速采用、确保供应弹性并展示差异化的临床价值

产业领导者应采取积极的策略，协调临床、商业和营运重点，以实现经导管肺动脉瓣治疗的长期价值。投资于产生严格的上市后证据，包括基于註册的疗效和真实世界绩效指标，为付款人和转诊中心建立令人信服的临床叙述。将对临床数据的承诺与模组化培训计划和基于模拟的监考相结合，将加速该疗法的采用，同时确保患者安全和一致的疗效。

在营运方面，我们将实现零件采购多元化，并尽可能地进行近岸外包，以减轻关税影响并确保供应的连续性。我们将及早与监管机构沟通，明确设备的改进路径，并利用前瞻性队列和实用性註册数据制定适应性证据计划。在商业方面，我们将针对终端用户细分市场，优化价值主张，例如，为门诊手术中心提供吞吐量和成本提案，为心臟病中心提供先进的病例支持和多学科伙伴关係，以及为医院提供全面的围手术全期护理方案。

最后，我们将与影像和数位医疗服务提供者建立策略合作伙伴关係，提供整合的规划工具，以减少诊疗流程的差异性。透过优先采用透明的定价模式和与结果挂钩的合同，使奖励与医疗系统和付款人保持一致，我们将在保障净利率和确保永续增长的同时，支持更广泛的医疗服务可及性。

透明、多方法的研究途径结合了临床访谈、监管调查、供应链分析和资料三角测量，确保获得可靠、可行的见解

本报告所采用的研究将一手资料、二手资料和结构化资料检验结合。主要方法包括对介入性心臟病专家、先天性心臟外科医生、采购负责人和行业高管进行深入访谈，以收集关于器械选择、操作流程和应用障碍的经验性见解。此外，我们还对同行评审的临床文献、监管部门的核准、临床註册摘要以及特定器械的安全沟通进行了结构化审查，以确保与最新的临床证据和安全信号保持一致。

采用资料三角测量法来协调现场访谈、临床报告和官方监管文件之间的差异，并强调资讯来源的可重复性和透明度。製造和供应链评估利用组件映射、供应商访谈和公开的贸易数据来识别风险的关键节点和潜在的缓解途径。分析框架结合了定性输入的主题编码、政策和关税影响的情境分析以及比较设备特性矩阵，以突出差异化因素。

品质保证包括由临床和市场分析师进行的多阶段同行评审、对主要来源引文的检验以及敏感性检查，以确保结论能够适应区域实践模式和监管时间表的差异。我们承认存在一些局限性，包括不同註册机构的临床报告标准存在差异，以及不断变化的政策环境，这些因素可能会随着时间的推移改变采购和报销的动态。

简洁的结论强调了临床证据、供应弹性和策略商业化的一致性，这是永续采用和对患者产生影响的先决条件。

经导管肺动脉瓣治疗正处于曲折点，技术创新、临床证据和策略商业化必须协调一致，才能实现永续的患者获益和永续的推广应用。改良的瓣膜设计、先进的影像技术和不断发展的治疗模式，拓展了经皮肺动脉瓣置换术的临床潜力。然而，营运方面的挑战，包括供应链弹性、关税压力以及对令人信服的真实世界证据的需求，仍然是决定推广速度和公平性的关键因素。

对于在该领域制定策略的相关人员来说，当务之急显而易见：投资于持久的临床证据，确保多元化的製造地，并根据门诊中心、心臟专科计画和医院系统的具体需求定製商业化方案。将这些要素与弹性价格设定框架和全面的培训相结合的组织，将最有能力将临床前景转化为持续的患者可及性和长期价值创造。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 针对高手术风险的儿童和成人患者的微创经导管肺动脉瓣植入手术激增
  • 扩大经导管肺动脉瓣治疗先天性右心室流出道功能障碍的适应症
  • 利用先进的影像导引和3D列印技术，越来越多地采用个人化瓣膜尺寸
  • 国内製造商的不断增加推动了新兴市场价格的下降和本土阀门的推出
  • 将生物可吸收材料整合到经导管肺动脉瓣设计中，以最大限度地减少长期併发症
  • 正在进行临床试验以评估新型经导管肺动脉瓣的长期血流动力学性能和安全性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 经导管肺动脉瓣市场（依瓣膜类型）

  • 球囊扩张阀
    • 旋律阀
    • SAPIEN经导管瓣膜
  • 自膨胀阀
    • Harmony经导管肺动脉瓣
    • 维纳斯 P 阀

9. 经导管肺动脉瓣市场（依应用）

  • 复杂病变
  • 肺逆流症
  • 肺动脉狭窄

10. 经导管肺动脉瓣市场（依最终用户）

  • 门诊手术中心
  • 心臟中心
  • 医院

11. 经导管肺动脉瓣市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 12 章。按组别分類的经导管肺动脉瓣市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 经导管肺动脉瓣市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Medtronic plc
    • Venus MedTech（Hangzhou）Co., Ltd.
    • TaeWoong Medical Industrial Co., Ltd.
    • Xeltis SA
    • Lifetech Scientific Corporation
    • Lepu Medical Technology（Beijing）Co., Ltd.
    • MicroPort Scientific Corporation
    • Umbra Valve Technologies BV
    • Jude Medical Inc
    • Braile Biomedica
Product Code: MRR-03168519576D

The Transcatheter Pulmonary Valve Market is projected to grow by USD 151.69 million at a CAGR of 10.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 69.76 million
Estimated Year [2025] USD 76.76 million
Forecast Year [2032] USD 151.69 million
CAGR (%) 10.19%

A comprehensive introduction to transcatheter pulmonary valve therapy highlighting clinical evolution, procedural adoption, and strategic implications for stakeholders

Transcatheter pulmonary valve therapy has transitioned from an experimental intervention into a clinically viable option that addresses significant unmet needs among patients with congenital and acquired right ventricular outflow tract dysfunction. The introduction of percutaneous valve systems has enabled clinicians to offer less invasive alternatives to repeat open-heart surgery, reducing perioperative morbidity and shortening recovery pathways for both pediatric and adult congenital populations. Procedural refinements, imaging advances, and a deeper understanding of patient selection criteria have collectively strengthened outcomes and expanded the clinical indications for catheter-based pulmonary valve replacement.

Clinical practice now emphasizes heart-team collaboration that integrates congenital cardiologists, interventionalists, cardiac surgeons, and advanced imaging specialists. This multidisciplinary approach optimizes device selection, access strategy, and post-procedural surveillance. As operators accumulate procedural experience and centers codify pathways for patient follow-up, safety profiles have improved while the threshold for treating symptomatic and asymptomatic lesions has evolved. Regulatory clearances and real-world registry data have further legitimized transcatheter pulmonary valve interventions, fostering broader adoption across tertiary referral centers and select ambulatory surgical settings.

From a strategic perspective, device manufacturers, health systems, and clinical investigators are positioned to translate technical advances into scalable care models. The pathway forward requires coordinated investments in training, post-market evidence generation, and supply chain resilience to ensure equitable access and consistent procedural performance across geographies and provider types.

An authoritative synthesis of the transformative technological, clinical, and operational shifts reshaping pulmonary valve therapy and provider strategy

The landscape for pulmonary valve therapies is undergoing transformative shifts driven by converging technological, clinical, and operational dynamics. Advances in valve design, including improvements in radial force profiles, tissue engineering, and delivery-system flexibility, are expanding anatomical applicability and reducing access-related challenges. Enhanced imaging modalities and fusion-guidance platforms enable precise positioning and sizing in complex right ventricular outflow tracts, lowering complication rates and expanding operator confidence in anatomies previously deemed high risk.

Concurrently, a shift in clinical paradigms has emerged as long-term valve durability and patient quality of life become central endpoints. Innovations in device retrievability and modular approaches support staged procedures and tailored therapies for diverse patient cohorts. Regulatory ecosystems are adapting to hybrid evidence models that combine randomized data with high-quality registries, accelerating conditional approvals in regions where unmet need is highest. Reimbursement conversations are likewise evolving, with payers increasingly attentive to value-based metrics such as reduced readmissions, shorter length of stay, and long-term functional improvement.

Operationally, centers of excellence are forming to concentrate expertise and streamline patient pathways, while partnerships between device developers and imaging firms are integrating predictive planning tools. As a result, the competitive landscape is shifting from single-product strategies to integrated solutions that bundle devices, imaging protocols, and clinical training, thereby redefining what it means to deliver high-value transcatheter pulmonary care.

A clear analysis of how the 2025 United States tariff changes are reshaping supply chains, procurement economics, and strategic manufacturing decisions in cardiac device sectors

The implementation of new tariff measures in the United States in 2025 has introduced a tangible lens through which device manufacturers and health providers are re-evaluating supply chain, procurement, and pricing strategies. Tariffs on imported components and assembled devices affect procurement economics, prompting manufacturers to assess localized production, nearshoring options, and alternative sourcing to preserve margin and maintain competitive pricing for hospital purchasers. These protective trade measures can increase lead times and transactional costs for organizations reliant on global supply networks, reinforcing the need for multi-sourcing and inventory buffers.

Clinical programs and hospital purchasers face the prospect of negotiating revised contract terms that account for import-related surcharges and potential variability in device availability. Health systems must balance the imperative of cost containment with clinical imperatives that prioritize patient outcomes; this often necessitates transparent dialogues between clinical leaders and procurement teams to align on acceptable trade-offs and priority access for high-risk patients. In parallel, manufacturers are accelerating efforts to diversify component suppliers, qualify domestic vendors, and invest in automated manufacturing to offset tariff-driven cost pressures.

Policy responses and procurement strategies will ultimately determine the extent to which tariffs alter device adoption trajectories. Stakeholders that proactively model tariff sensitivities, secure contingency manufacturing capacity, and communicate clinical value compellingly to payers and health system buyers will most effectively mitigate the operational disruptions introduced in 2025. This adaptive posture reduces risk to patients and preserves momentum for innovation and broader clinical adoption.

A strategic breakdown of device, clinical, and end-user segmentation revealing where product features and patient needs intersect to shape commercial and clinical pathways

A granular segmentation framework illuminates where clinical demand, product differentiation, and end-user behavior intersect to shape strategy. Based on valve type, the landscape is characterized by two dominant device approaches: balloon expandable designs and self-expanding systems. Balloon expandable valves include well-established platforms such as the Melody valve and the Sapien transcatheter valve, which have proven utility in specific valve sizes and conduit anatomies. Self-expanding systems are represented by technologies like the Harmony transcatheter pulmonary valve and the Venus P-Valve, which offer conformability and radial adaptation suited to broader and often irregular right ventricular outflow tracts. The technical trade-offs between these valve types inform clinical selection criteria, inventory management, and training requirements across centers.

Application-based segmentation further refines clinical pathways and evidence needs. Patient presentations span combined lesions, pulmonary regurgitation, and pulmonary stenosis, each with distinct hemodynamic considerations and procedural planning imperatives. Devices compatible with mixed pathology must demonstrate versatility in sealing, anchoring, and hemodynamic performance, while those intended primarily for stenosis or regurgitation can optimize for low-profile delivery or enhanced radial support, respectively. End-user segmentation underscores where adoption manifests operationally: ambulatory surgical centers, cardiac centers, and hospitals each have unique infrastructure, case mix, and purchasing models. Ambulatory surgical centers may prioritize throughput and same-day discharge protocols, cardiac centers focus on complex cases and multidisciplinary pathways, and hospitals balance acute care capacity with broader inpatient capabilities.

Understanding how valve type, clinical application, and end-user environment interact enables manufacturers and providers to align product portfolios, training programs, and commercialization plans with the practical realities of device deployment and outcomes monitoring.

A concise regional intelligence overview that contrasts adoption dynamics, regulatory environments, and commercialization pathways across key global territories

Regional dynamics play a central role in shaping access, regulatory pathways, and commercial execution. In the Americas, established centers of excellence and a mature interventional cardiology ecosystem create a favorable environment for early adoption of advanced transcatheter pulmonary solutions, supported by robust clinical networks and well-developed reimbursement frameworks. Market entry and scale-up efforts in this region benefit from high procedural volumes, concentrated specialist expertise, and active clinical research communities that generate post-market safety and performance data.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory diversity, variable reimbursement pathways, and disparate infrastructure influence adoption rates. Western European markets typically demonstrate rapid uptake when clinical evidence supports improved outcomes, whereas emerging markets in the broader EMR and African corridors prioritize cost-effective solutions and resilient supply chains. Strategic partners in these geographies often require tailored pricing, capacity-building programs, and local evidence generation to facilitate uptake.

Asia-Pacific exhibits accelerated investment in congenital and structural heart disease programs alongside a strategic emphasis on domestic manufacturing and innovation hubs. Several countries in this region are scaling specialized cardiac centers and driving localized clinical registries that inform device adaptation for population-specific anatomies. Cross-border collaboration and technology transfer initiatives are increasingly common as manufacturers navigate regulatory pathways and local clinical expectations.

An incisive overview of competitive positioning, alliance strategies, and innovation focus areas shaping company-level differentiation in pulmonary valve therapies

The competitive environment in transcatheter pulmonary valves reflects a mix of established cardiovascular device manufacturers and agile specialized innovators. Leading organizations prioritize a balanced approach that couples device engineering with clinical evidence generation and provider education. Partnerships between device makers and advanced imaging firms are becoming commonplace, enabling more reliable pre-procedure planning and intra-procedural guidance. Strategic collaborations with contract manufacturers and material science firms also enhance manufacturing scalability and component quality control.

Innovation pipelines emphasize durability, deliverability, and adaptability to challenging anatomies, with an increasing number of entrants exploring tissue treatments and anti-calcification technologies to extend valve longevity. Commercial strategies focus on bundled service offerings that include proctoring, simulation training, and outcomes support to reduce the learning curve for new adopters. In parallel, some companies are pursuing targeted geographic expansion through local distributors and clinical partnerships, while others invest in direct-market presence where regulatory and reimbursement conditions favor premium positioning.

Mergers, acquisitions, and licensing agreements continue to be strategic levers for achieving category leadership, particularly where complementary imaging, supply chain, or reimbursement expertise can be integrated. Organizations that align robust clinical programs with scalable manufacturing and clear value messaging are best positioned to capture sustained clinical traction and institutional adoption.

Actionable recommendations for clinical, manufacturing, and commercial leaders to accelerate adoption, secure supply resilience, and demonstrate differentiated clinical value

Industry leaders should pursue a proactive strategy that aligns clinical, commercial, and operational priorities to capture long-term value in transcatheter pulmonary valve care. Invest in rigorous post-market evidence generation that includes registry-based outcomes and real-world performance metrics to build a compelling clinical narrative for payers and referral centers. Combine these clinical data efforts with modular training programs and simulation-based proctoring to accelerate adoption while maintaining patient safety and consistent procedural outcomes.

From an operational standpoint, diversify component sourcing and pursue nearshoring where feasible to mitigate tariff exposure and ensure continuity of supply. Engage early with regulatory bodies to clarify pathways for incremental device enhancements and to design adaptive evidence plans that leverage both prospective cohorts and pragmatic registry data. On the commercial front, craft value propositions tailored to end-user segments: emphasize throughput and cost-efficiency for ambulatory surgical facilities, advanced case support and multidisciplinary partnerships for cardiac centers, and comprehensive perioperative care bundles for hospitals.

Finally, pursue strategic collaborations with imaging and digital-health providers to deliver integrated planning tools that reduce procedural variability. Prioritize transparent pricing models and outcomes-linked contracting to align incentives with health systems and payers, thereby supporting broader access while protecting margin and ensuring sustainable growth.

A transparent, multi-method research approach combining clinical interviews, regulatory review, supply-chain analysis, and data triangulation to ensure robust, actionable insights

The research underpinning this report blends primary qualitative engagement with rigorous secondary synthesis and structured data validation. Primary methods included in-depth interviews with interventional cardiologists, congenital heart surgeons, procurement leaders, and industry executives to capture experiential insights on device selection, procedural workflows, and adoption barriers. These conversations were complemented by structured reviews of peer-reviewed clinical literature, regulatory approvals, clinical registry summaries, and device-specific safety communications to ensure alignment with the latest clinical evidence and safety signals.

Data triangulation was applied to reconcile discrepancies between field interviews, clinical reports, and public regulatory documentation, with a focus on reproducibility and source transparency. Manufacturing and supply-chain assessments utilized component mapping, supplier interviews, and publicly available trade data to identify critical nodes of risk and potential mitigation pathways. The analytical framework incorporated thematic coding of qualitative input, scenario analysis for policy and tariff impacts, and comparative device feature matrices to surface differentiators.

Quality assurance included multi-level peer review by clinical and market analysts, verification of primary source citations, and sensitivity checks to ensure conclusions remain robust given variations in regional practice patterns and regulatory timelines. Limitations are acknowledged, including variability in clinical reporting standards across registries and evolving policy environments that may alter procurement and reimbursement dynamics over time.

A concise conclusion emphasizing the alignment of clinical evidence, supply resilience, and strategic commercialization as prerequisites for sustainable adoption and patient impact

Transcatheter pulmonary valve therapy stands at an inflection point where technical innovation, clinical evidence, and strategic commercialization must align to achieve durable patient benefit and sustainable adoption. The confluence of improved valve designs, advanced imaging, and evolving treatment paradigms has expanded the clinical promise of percutaneous pulmonary valve replacement. However, operational challenges such as supply-chain resilience, tariff pressures, and the need for convincing real-world evidence remain critical determinants of the pace and equity of adoption.

For stakeholders crafting strategy in this space, the imperative is clear: invest in durable clinical evidence, secure diversified manufacturing footprints, and tailor commercialization approaches to the specific needs of ambulatory centers, cardiac specialty programs, and hospital systems. Organizations that integrate these elements with flexible pricing frameworks and comprehensive training will be best placed to convert clinical promise into consistent patient access and long-term value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in minimally invasive transcatheter pulmonary valve implantations for high surgical risk pediatric and adult patients
  • 5.2. Introduction of next generation self-expanding transcatheter pulmonary valves with enhanced durability and reduced reintervention rates
  • 5.3. Expansion of transcatheter pulmonary valve indications to treat native right ventricular outflow tract dysfunction
  • 5.4. Growing adoption of advanced imaging guidance and three dimensional printing for personalized valve sizing
  • 5.5. Rising presence of domestic manufacturers driving price reductions and regional valve launches in emerging markets
  • 5.6. Integration of bioresorbable materials into transcatheter pulmonary valve design to minimize long term complications
  • 5.7. Ongoing clinical trials assessing long term hemodynamic performance and safety of novel transcatheter pulmonary valves

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Pulmonary Valve Market, by Valve Type

  • 8.1. Balloon Expandable Valve
    • 8.1.1. Melody Valve
    • 8.1.2. Sapien Transcatheter Valve
  • 8.2. Self Expanding Valve
    • 8.2.1. Harmony Transcatheter Pulmonary Valve
    • 8.2.2. Venus P-Valve

9. Transcatheter Pulmonary Valve Market, by Application

  • 9.1. Combined Lesions
  • 9.2. Pulmonary Regurgitation
  • 9.3. Pulmonary Stenosis

10. Transcatheter Pulmonary Valve Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Cardiac Centers
  • 10.3. Hospitals

11. Transcatheter Pulmonary Valve Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Transcatheter Pulmonary Valve Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Transcatheter Pulmonary Valve Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Medtronic plc
    • 14.3.2. Venus MedTech (Hangzhou) Co., Ltd.
    • 14.3.3. TaeWoong Medical Industrial Co., Ltd.
    • 14.3.4. Xeltis SA
    • 14.3.5. Lifetech Scientific Corporation
    • 14.3.6. Lepu Medical Technology (Beijing) Co., Ltd.
    • 14.3.7. MicroPort Scientific Corporation
    • 14.3.8. Umbra Valve Technologies B.V.
    • 14.3.9. Jude Medical Inc
    • 14.3.10. Braile Biomedica

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. TRANSCATHETER PULMONARY VALVE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. TRANSCATHETER PULMONARY VALVE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSCATHETER PULMONARY VALVE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 91. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 97. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 106. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 108. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 118. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 154. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 192. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 204. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 205. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 206. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 207. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 228. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 240. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 241. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 242. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 243. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 252. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 253. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 254. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 255. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 265. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 274. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 275. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 276. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 277. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 284. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 285. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 286. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 287. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 294. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 295. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 296. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 297. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM TRANSCATHETER PULMONARY VALVE MARKET SIZ